Lilly to Present at J.P. Morgan Healthcare Conference

INDIANAPOLIS, Jan. 5, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015. John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer will make a formal presentation from 11:30 a.m. to 11:55 a.m. PST.

A live audio webcast will be available on the Webcasts & Presentations section of Lilly's Investor website at http://investor.lilly.com/events.cfm. Subsequently, a replay of Dr. Lechleiter's presentation will be available on this same website for approximately 90 days.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.  F-LLY   

Refer to:
(317) 277-6524; [email protected]; Lauren Zierke (Media)  
(317) 655-6874; [email protected]; Phil Johnson (Investor)

Eli Lilly and Company logo

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lilly-to-present-at-jp-morgan-healthcare-conference-300015889.html

SOURCE Eli Lilly and Company

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.